Pfizer and Akzo Nobel's Organon enter global collaboration for potential new psychotropic treatment
Pfizer Inc. and Organon, the human pharmaceutical business unit of Akzo Nobel, announced they have entered into a global agreement for the exclusive worldwide development and commercialization of Organon's asenapine, a potential new psychotropic medication for the treatment of a variety of disorders that is beginning phase III trials in schizophrenia and bipolar disorder.
Under terms of the agreement, which is subject to government approval, the companies will collaborate on the clinical development and manufacturing of asenapine, and co-promote the product in the United States, European Union, Japan and other markets. Pfizer will make an initial payment of U.S. dollar 100 million and up to U.S. dollar 270 million in milestone payments contingent upon regulatory approvals and launch of asenapine in the United States, Europe and Japan as well as attainment of certain agreed-upon sales levels. Further terms of the agreement were not disclosed.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
